13F Holdings
中文EN

AURA Aura Biosciences, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1501796 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-28.6%
TTM EPS YoY16.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-61.7%
ROA-53.5%
ROIC (approx.)-64.7%
Asset turnover—

Leverage & solvency

Liabilities / assets10.6%
Debt / equity0.00x
Current ratio14.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$90.30M$73.30M$65.23M$42.24M$25.16M
SG&A expense$22.49M$22.81M$19.76M$18.06M$10.09M
Operating income-$112.79M-$96.12M-$84.99M-$60.30M-$35.25M
Pretax income-$106.08M-$86.81M-$76.27M-$58.76M—
Income tax$108,000$112,000$137,000$0$0
Net income-$106.19M-$86.92M-$76.41M-$58.76M-$35.25M
EBITDA-$111.66M-$94.89M-$83.70M-$59.12M-$34.42M
EPS (basic)-1.76-1.75-1.93-1.96-8.95
EPS (diluted)-1.76-1.75-1.93-1.96-8.95
Weighted avg. shares (diluted)60.34M49.65M39.62M29.94M5.16M
Balance sheet
Cash & equivalents$59.52M$31.69M$41.06M$121.58M$149.06M
Current assets$149.74M$160.62M$231.79M$196.70M$153.70M
PP&E, net$2.62M$3.21M$3.15M$5.37M$5.25M
Total assets$169.43M$182.50M$255.07M$223.94M$160.03M
Current liabilities$18.38M$14.91M$12.36M$10.46M$7.36M
Total liabilities$32.52M$30.53M$29.23M$28.35M$7.71M
Shareholders' equity$136.91M$151.97M$225.85M$195.58M$152.31M
Shares outstanding63.59M50.00M49.35M37.77M29.21M
Cash flow statement
Operating cash flow-$84.74M-$79.81M-$63.85M-$54.60M-$32.41M
Capital expenditure$447,000$1.25M$709,000$1.09M$2.12M
Free cash flow-$85.19M-$81.06M-$64.56M-$55.70M-$34.53M
Investing cash flow$35.59M$68.82M-$113.96M-$67.87M-$2.12M
Financing cash flow$77.16M$1.59M$97.29M$95.63M$166.26M
Depreciation & amortization$1.13M$1.22M$1.29M$1.18M$831,000
Stock-based compensation$14.32M$11.72M$8.77M$6.41M$2.31M

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.